Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy

Drug Category: Array
Conference Category: Array
Lead Author: Mato A, et al.
Published Date: 02/12/2020
Download Link: https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020007376/474377/Phase-2-Study-of-the-Safety-and-Efficacy-of?redirectedFrom=fulltext
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top